Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.84 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.84 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.84 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.84 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.47 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.47 |
| ▸ | KCNK3 known ✓ | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 known ✓ | Q9NPC2 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | WHR1 | P49842 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296279 | 0.99 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DEGFR | |
| Phosphoric Acid Monomethyl Ester SCHEMBL4264353 | 0.95 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DEGFR | |
| Methanesulfonic Acid Methyl Ester SCHEMBL4261958 | 0.94 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL3893441 | 0.94 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL296765 | 0.93 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL371380 | 0.93 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL297387 | 0.92 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL1942230 | 0.91 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL1942703 | 0.91 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DADORA3 | |
| Lotamilast SCHEMBL369445 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357495-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | Dermavant Sciences GmbH (CH) | 2019-07-23 | — | — | US | disclosed |
| US-20190134036-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-3463366-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-10206925-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | EISAI R&D MANAGEMENT CO, LTD. (JP) | 2019-02-19 | — | — | US | disclosed |
| WO-2017214289-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348311-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2017-12-07 | — | — | US | disclosed |
| US-8513269-B2 | Preparation for external use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2202229-B1 | NOVEL PREPARATION FOR EXTERNAL USE | EISAI R&D MAN CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1992622-B1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7939540-B2 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20110021545-A1 | NOVEL PREPARATION FOR EXTERNAL USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2202229-A1 | NOVEL PREPARATION FOR EXTERNAL USE | Eisai R&D Management Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-1992622-A1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206925-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | ITCH, HRH4, HRH1 | PDE4A 1280/4885PDE4B 1378/4885PDE4C 2057/4885 |
| US-20170348311-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-10357495-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20190134036-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20110021545-A1 | NOVEL PREPARATION FOR EXTERNAL USE | SLC26A4, SLC6A15, SLC6A19 | PDE4A 3486/4885PDE4B 3375/4885PDE4C 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.